Bemegride

Bemegride

SCHEMBL601065

CCC1(C)CC(=O)NC(=O)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 1.00
KDM4E B2RXH2 1/20 1.00
CYP2C19 P33261 1/20 1.00
TSHR P16473 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
CRBN Q96SW2 3/20 0.36
CYP19A1 P11511 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.34
KMT2A Q03164 1/20 0.34
MAPK1 P28482 1/20 0.33
POLB P06746 1/20 0.33
CTSK P43235 1/20 0.31
TOP2A P11388 1/20 0.31
TOP2B Q02880 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11075525 0.80 KDM4E (0.67) LMNAKDM4ECYP2C19TSHRNPSR1
SCHEMBL7436133 0.78
SCHEMBL11079770 0.76 LMNA (0.61) LMNAKDM4ECYP2C19TSHRNPSR1
SCHEMBL7439817 0.75 KDM4E (0.59) LMNAKDM4ECYP2C19TSHRNPSR1
SCHEMBL4787173 0.74 KDM4E (0.58) LMNAKDM4ECYP2C19TSHRNPSR1
SCHEMBL4998752 0.72 KDM4E (0.56) LMNAKDM4ECYP2C19TSHRNPSR1
SCHEMBL193896 0.72 KDM4E (0.56) LMNAKDM4ECYP2C19TSHRNPSR1
SCHEMBL9312505 0.72 CYP2C19 (0.56) LMNAKDM4ECYP2C19TSHRNPSR1
SCHEMBL1352364 0.71 KDM4E (0.55) LMNAKDM4ECYP2C19TSHRNPSR1
SCHEMBL9471261 0.71 KDM4E (0.55) LMNAKDM4ECYP2C19TSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 956 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025010293-A2 MEK IMMUNE ONCOLOGY INHIBITOR PHARMACEUTICAL COMPOSITIONS IMMUNEERING CORPORATION (US) 2025-01-09 WO claimed
US-20240350644-A1 STEREOCOMPLEXES FOR THE DELIVERY OF ANTI-CANCER AGENTS TIEN DER YANG (US) 2024-10-24 US claimed
US-12029792-B2 Stereocomplexes for the delivery of anti-cancer agents TIEN DER YANG (US) 2024-07-09 US claimed
CN-113727985-B Compound and organic light emitting device comprising the same 株式会社LG化学 2024-04-16 CN claimed
US-20230405018-A1 FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS BEXSON BIOMEDICAL, INC. 2023-12-21 US claimed
US-20230398197-A1 COLDWATER DISEASE VACCINE COMPRISING AN ATTENUATED FLAVOBACTERIUM PSYCHROPHILUM STRAIN UNIVERSITY OF IDAHO (US) 2023-12-14 US claimed
US-20230395255-A1 METHODS FOR IDENTIFYING AND TARGETING THE MOLECULAR SUBTYPES OF ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-12-07 US claimed
EP-4247386-A1 FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS Bexson Biomedical, Inc. (US) 2023-09-27 EP claimed
CN-115323060-B Fish nuclear gene molecular marker primer, molecular marker and molecular marker database 中国水产科学研究院珠江水产研究所 2023-08-01 CN claimed
EP-4137527-A1 STEREOCOMPLEXES FOR THE DELIVERY OF ANTI-CANCER AGENTS TIEN, Der-Yang (US) 2023-02-22 EP claimed
WO-2001001932-A2 OLIGOSACCHARIDE ALDONIC ACIDS AND THEIR TOPICAL USE YU RUEY J (US) 2001-01-11 WO claimed
WO-2000059481-A1 PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT PHARMAQUEST LTD. (BM) 2000-10-12 WO claimed
WO-2000059479-A1 PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE PHARMAQUEST LTD. (BM) 2000-10-12 WO claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
CN-2329059-Y Quick look-up instrument for incompatibility of drugs in a prescription of 159 kind of injections GU CHUNWEI (CN) 1999-07-14 CN claimed
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 US claimed
EP-0110955-B1 BRAIN-SPECIFIC DRUG DELIVERY UNIV FLORIDA (US) 1995-08-23 EP claimed
EP-0224283-A2 Brain-specific drug delivery UNIVERSITY OF FLORIDA (US) 1987-06-03 EP claimed
EP-0222425-A2 Brain-specific drug delivery UNIVERSITY OF FLORIDA (US) 1987-05-20 EP claimed
EP-0218300-A2 Brain-specific drug delivery UNIVERSITY OF FLORIDA (US) 1987-04-15 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230405018-A1 FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS GABBR1, GABBR2, GABRB2 LMNA 4363/4885KDM4E 3062/4885CYP2C19 331/4885
US-12029792-B2 Stereocomplexes for the delivery of anti-cancer agents TOP2A, TSG101, TOP1 LMNA 2051/4885KDM4E 4639/4885CYP2C19 4324/4885
US-20240350644-A1 STEREOCOMPLEXES FOR THE DELIVERY OF ANTI-CANCER AGENTS TOP2A, TSG101, TOP1 LMNA 2051/4885KDM4E 4639/4885CYP2C19 4324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.